EXACTECH, INC. (NASDAQ:EXAC) Files An 8-K Results of Operations and Financial Condition

0

EXACTECH, INC. (NASDAQ:EXAC) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition

The disclosure set forth in Item 7.01 to this Current Report on
Form 8-K is incorporated into this Item 2.02 by reference.
Item 7.01. Regulation FD Disclosure.
On February 21, 2017, Exactech, Inc. (the Company) issued a press
release disclosing certain financial information about the
Company. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is hereby incorporated by
reference in this Item 7.01.
The press release attached as an exhibit to this report contain
various forward looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which represent
the Companys expectations or beliefs concerning future events,
including, but not limited to, statements regarding levels of and
expected growth in sales of the Companys products. When used in
the press release or this report, the terms anticipate, believe,
estimate, expect and intend and words or phrases of similar
import, as they relate to the Company or its subsidiaries or its
management, are intended to identify forward- looking statements.
These forward-looking statements are further qualified by
important factors that could cause actual results to differ
materially from those in the forward-looking statements. These
factors include, without limitation, the effect of competitive
pricing, the Companys dependence on the ability of its
third-party suppliers to produce components on a cost-effective
basis to the Company, market acceptance of the Companys products,
the outcome of litigation, the availability of third-party
reimbursement for the Companys products, high inventory
maintenance requirements, the Companys ability to protect its
intellectual property, dedication of substantial resources
towards research and development efforts, product liability risks
and the effects of governmental regulation. Results actually
achieved may differ materially from expected results included in
these statements as a result of these or other factors, including
those risks disclosed in the reports filed by the Company with
the Securities and Exchange Commission. Exactech undertakes no
obligation to update, and the Company does not have a policy of
updating or revising, these forward-looking statements. The
information in this report will not be deemed an admission as to
the materiality of any information required to be disclosed
solely to satisfy the requirements of Regulation FD. The
furnishing of this information is not intended to, and does not,
constitute a determination or admission by the Company that such
information is material or complete, or that investors should
consider this information before making an investment decision
with respect to any security of the Company.
The information contained in Items 2.02 and 7.01 to this Current
Report on Form 8-K, including Exhibit 99.1, attached hereto,
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing by the Company under the
Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release issued by the Company on February 21,
2017.


About EXACTECH, INC. (NASDAQ:EXAC)

Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes surgical instruments, bone cement and other implant product lines. The Company offers knee implant systems, including Exactech Knee System and Optetrak Logic. It offers various products and services for the healing and regeneration of bone and soft tissue. Its hip solutions address the continuum of hip arthroplasty. It offers solutions for shoulders with traumatic injuries. Its joint replacement products are used to repair or replace joints that have deteriorated as a result of injury or disease.

EXACTECH, INC. (NASDAQ:EXAC) Recent Trading Information

EXACTECH, INC. (NASDAQ:EXAC) closed its last trading session 00.00 at 25.15 with 22,620 shares trading hands.